1. Home
  2. SYBT vs WVE Comparison

SYBT vs WVE Comparison

Compare SYBT & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stock Yards Bancorp Inc.

SYBT

Stock Yards Bancorp Inc.

HOLD

Current Price

$63.88

Market Cap

2.0B

Sector

Finance

ML Signal

HOLD

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

HOLD

Current Price

$6.33

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SYBT
WVE
Founded
1904
2012
Country
United States
Singapore
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.4B
IPO Year
2009
2015

Fundamental Metrics

Financial Performance
Metric
SYBT
WVE
Price
$63.88
$6.33
Analyst Decision
Hold
Strong Buy
Analyst Count
4
16
Target Price
$79.00
$31.19
AVG Volume (30 Days)
164.1K
4.2M
Earning Date
04-22-2026
05-07-2026
Dividend Yield
1.96%
N/A
EPS Growth
22.11
N/A
EPS
4.75
N/A
Revenue
$23,406,000.00
$3,704,000.00
Revenue This Year
$16.83
$0.34
Revenue Next Year
$8.40
$83.30
P/E Ratio
$13.76
N/A
Revenue Growth
3.37
149.43
52 Week Low
$60.75
$5.02
52 Week High
$83.83
$21.73

Technical Indicators

Market Signals
Indicator
SYBT
WVE
Relative Strength Index (RSI) 45.71 21.83
Support Level $61.96 N/A
Resistance Level $71.41 $8.15
Average True Range (ATR) 1.69 0.78
MACD 0.28 -0.65
Stochastic Oscillator 55.07 14.23

Price Performance

Historical Comparison
SYBT
WVE

About SYBT Stock Yards Bancorp Inc.

Stock Yards Bancorp Inc operates as a bank. The bank has two reportable operating segments namely Commercial Banking and Wealth Management and Trust. Its services include loan and deposit services, cash management services, securities brokerage activities, mortgage origination, and others. It generates the majority of its revenue from the Commercial Banking segment.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: